ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Clean headline: revenue +16% YoY, EBITDA 34%, PAT +14%. Growth leans on deferred sales and rising top-10 customer concentration (46%). US recovery is only hoped for.
Q2 FY27 consolidated revenue ₹2,145mn (+16% YoY), EBITDA ₹721mn (+20%, 34% margin), PAT ₹512mn (+14%). H1 revenue +10%, PAT +5%. Industrial bio-processing and animal nutrition lead growth.
Q1FY27 was muted with flat revenue growth and EBITDA contraction due to higher energy costs and standard revenue reversal accounting. Management maintains double-digit growth targets despite current geopolitical and US-market headwinds.
Advanced Enzyme reported Q1 FY27 revenue of ₹1,898 mn, up 2% YoY, despite a 10% EBITDA decline. Segment performance was mixed, with specialized manufacturing and bio-processing showing strong growth.
Advanced Enzyme reported its highest-ever quarterly and annual revenue for FY26. Management focused on expanding R&D, human healthcare flagship growth, and navigating global supply chain disruptions.